169 related articles for article (PubMed ID: 16390319)
1. Parameters of LRP5 from a structural and molecular perspective.
Johnson ML; Summerfield DT
Crit Rev Eukaryot Gene Expr; 2005; 15(3):229-42. PubMed ID: 16390319
[TBL] [Abstract][Full Text] [Related]
2. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way.
He X; Semenov M; Tamai K; Zeng X
Development; 2004 Apr; 131(8):1663-77. PubMed ID: 15084453
[TBL] [Abstract][Full Text] [Related]
3. A cell-based Dkk1 binding assay reveals roles for extracellular domains of LRP5 in Dkk1 interaction and highlights differences between wild-type and the high bone mass mutant LRP5(G171V).
Murrills RJ; Matteo JJ; Bhat BM; Coleburn VE; Allen KM; Chen W; Damagnez V; Bhat RA; Bex FJ; Bodine PV
J Cell Biochem; 2009 Dec; 108(5):1066-75. PubMed ID: 19746449
[TBL] [Abstract][Full Text] [Related]
4. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
Levasseur R; Lacombe D; de Vernejoul MC
Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
[TBL] [Abstract][Full Text] [Related]
5. Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins.
Brennan K; Gonzalez-Sancho JM; Castelo-Soccio LA; Howe LR; Brown AM
Oncogene; 2004 Jun; 23(28):4873-84. PubMed ID: 15064719
[TBL] [Abstract][Full Text] [Related]
6. The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo.
Bryja V; Andersson ER; Schambony A; Esner M; Bryjová L; Biris KK; Hall AC; Kraft B; Cajanek L; Yamaguchi TP; Buckingham M; Arenas E
Mol Biol Cell; 2009 Feb; 20(3):924-36. PubMed ID: 19056682
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
Ferrari SL; Deutsch S; Antonarakis SE
Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
[TBL] [Abstract][Full Text] [Related]
8. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
[TBL] [Abstract][Full Text] [Related]
9. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
10. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.
Gong Y; Slee RB; Fukai N; Rawadi G; Roman-Roman S; Reginato AM; Wang H; Cundy T; Glorieux FH; Lev D; Zacharin M; Oexle K; Marcelino J; Suwairi W; Heeger S; Sabatakos G; Apte S; Adkins WN; Allgrove J; Arslan-Kirchner M; Batch JA; Beighton P; Black GC; Boles RG; Boon LM; Borrone C; Brunner HG; Carle GF; Dallapiccola B; De Paepe A; Floege B; Halfhide ML; Hall B; Hennekam RC; Hirose T; Jans A; Jüppner H; Kim CA; Keppler-Noreuil K; Kohlschuetter A; LaCombe D; Lambert M; Lemyre E; Letteboer T; Peltonen L; Ramesar RS; Romanengo M; Somer H; Steichen-Gersdorf E; Steinmann B; Sullivan B; Superti-Furga A; Swoboda W; van den Boogaard MJ; Van Hul W; Vikkula M; Votruba M; Zabel B; Garcia T; Baron R; Olsen BR; Warman ML;
Cell; 2001 Nov; 107(4):513-23. PubMed ID: 11719191
[TBL] [Abstract][Full Text] [Related]
11. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
Williams BO; Insogna KL
J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
13. Cloning and expression of Xenopus Lrp5 and Lrp6 genes.
Houston DW; Wylie C
Mech Dev; 2002 Sep; 117(1-2):337-42. PubMed ID: 12204281
[TBL] [Abstract][Full Text] [Related]
14. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
15. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.
Balemans W; Van Hul W
Endocrinology; 2007 Jun; 148(6):2622-9. PubMed ID: 17395706
[TBL] [Abstract][Full Text] [Related]
16. Wnt7b activates canonical signaling in epithelial and vascular smooth muscle cells through interactions with Fzd1, Fzd10, and LRP5.
Wang Z; Shu W; Lu MM; Morrisey EE
Mol Cell Biol; 2005 Jun; 25(12):5022-30. PubMed ID: 15923619
[TBL] [Abstract][Full Text] [Related]
17. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity.
Tolwinski NS; Wehrli M; Rives A; Erdeniz N; DiNardo S; Wieschaus E
Dev Cell; 2003 Mar; 4(3):407-18. PubMed ID: 12636921
[TBL] [Abstract][Full Text] [Related]
18. LRP6 dimerization through its LDLR domain is required for robust canonical Wnt pathway activation.
Chen J; Yan H; Ren DN; Yin Y; Li Z; He Q; Wo D; Ho MS; Chen Y; Liu Z; Yang J; Liu S; Zhu W
Cell Signal; 2014 May; 26(5):1068-74. PubMed ID: 24412751
[TBL] [Abstract][Full Text] [Related]
19. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.
Cheung WM; Jin LY; Smith DK; Cheung PT; Kwan EY; Low L; Kung AW
Bone; 2006 Sep; 39(3):470-6. PubMed ID: 16679074
[TBL] [Abstract][Full Text] [Related]
20. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.
Van Wesenbeeck L; Cleiren E; Gram J; Beals RK; Bénichou O; Scopelliti D; Key L; Renton T; Bartels C; Gong Y; Warman ML; De Vernejoul MC; Bollerslev J; Van Hul W
Am J Hum Genet; 2003 Mar; 72(3):763-71. PubMed ID: 12579474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
